Abstract. Aurora-A/BTAK/STK15 gene which encodes a centrosome-associated kinase is located on chromosome 20q13.2, a highly amplified region in various human tumors. Recent studies have demonstrated the overexpression and amplification of Aurora-A in many malignant human cancers. The purpose of this study was to investigate the amplification and expression of Aurora-A in esophageal squamous cell carcinoma. Amplification of Aurora-A was determined by fluorescence in situ hybridization in 7 esophageal cancer cell lines and real-time PCR in 29 esophageal cancer samples. We detected Aurora-A expression in 7 esophageal cancer cell lines and 38 esophageal cancers samples by semi-quantitative reverse transcription-PCR and Western blot hybridization. The amplification of Aurora-A was detected in 27 of 29 (93.1%) esophageal cancer samples and 6 of 7 (85.7%) cancer cell lines. Aurora-A was overexpressed in 27 of 38 (71.1%) esophageal cancer samples and all 7 esophageal cancer cell lines. We conclude that Aurora-A is amplified and overexpressed in esophageal squamous cancer.
Introduction
The centrosomes are important for cells to maintain genomic stability through establishment of bipolar spindles during cell division, which could allow equal segregation of replicated chromosome to split into two daughter cells. The centrosomal function is strictly regulated by various proteins. Aurora kinase family, a conserved mitotic serine/threonine kinase family, played a vital role in regulating the centrosomal and microtubule function, ensuring accurate chromosome segregation and efficient completion of cytokinesis (1, 2) . Among the three members of this family, Aurora-A, attracted most attention because Aurora-A gene is mapped to chromosome 20q13.2, a region amplified commonly in epithelial cancers (3) (4) (5) (6) .
Amplification and/or overexpression of Aurora-A is detected in several types of tumors, including gastric cancer, bladder cancer, gliomas and hepatocellular cancers (7) (8) (9) (10) (11) (12) . Combining with the studies that overexpression of Aurora-A can transform NIH3T3 and Rat1 cells (13, 14) and increase the incidence of breast cancer in transgene mouse (15) , most researchers would consider Aurora-A as an oncogene.
ESCC is the fourth most prevalent malignancy in China, but the molecular mechanism for the tumorigenesis of esophageal cancer remains to be elucidated. Gain of chromosome 20q was often observed in ESCC (16) (17) (18) (19) (20) . There are no studies investigating DNA status of oncogene Aurora-A located on the 20q in ESCC despite recent reports showing the overexpression of Aurora-A in ESCC (12, 21) . Therefore, to further reveal the possible role of Aurora-A in esophageal cancer, we detected the DNA copies and expression level of Aurora-A in both esophageal cancer cells lines and primary tumor samples. Fresh samples were dissected manually to remove connective tissues and stored immediately at -80˚C until analyzed. The corresponding normal tissues were obtained from the distant edge of dissected esophagus without carcinoma cell invasion by pathological diagnosis. Every tissue sample contained over 80% of normal or tumor epithelial cells. (FISH) . Cells were treated with 1 μg/ml colchicines overnight. Then the metaphase cell slides were made according to standard protocol.
Materials and methods

Cell
Fluorescence in situ hybridization
Dual-color FISH was undertaken to detect 20q13.2 amplification in esophageal cancer cell lines. We co-hybridized an Aurora-A specific BAC probe (kindly provided by Dr Subrata Sen and Ms. Hongyi Zhou, University of Texas, M.D. Anderson Cancer Center) with a chromosome 20 specific centromere probe. The probes were labeled with biotin or digoxin by nick translation using Nick Translation Kit (Gibco/ BRL, Rockville, MD, USA). Hybridization was performed at 37˚C for 48 h in a moist chamber. After hybridization, the slides were washed in 50% formamide/2X SSC three times for 5 min each, followed by washes in 2X SSC three times for 5 min each time. Then the slides were blocked by 4X SSCB (4X SSC with 0.5% Blocking Regent bought from Roche 0.02% NaN 3 ) at room temperature for 30 min. The slides were incubated with Avidin-FITC in wet chamber at 37˚C for 60 min followed by three washings at room temperature for 5 min in 4X SSC. Amplification of the signals was performed by biotinylated anti-avidin antibody (Vector Laboratories, Burlington, Canada). At 37˚C for 60 min in a moist chamber followed by three washings at room temperature with 5 min wash in 4X SSC. A final incubation with Avidin-FITC and Rhodamine-anti-digoxigenin (Roche, Mannheim, Germany) (working solution: 5 μg Avidin-FITC/ml in 4X SSC, 0.5% blocking reagent, 0.2% NaN 3 ) was done at 37˚C for 60 min in a moist chamber followed by three washings at room temperature for 5 min in 4X SSCB. The nuclei were counterstained with DAPI.
The 20q13. Five microgram of total-RNA extracted from paired esophageal carcinoma was used as template respectively to synthesize cDNA in 25 μl reaction mixture with 2.5 mM oligo(dT) primers and M-MLV Reverse Transcriptase (Promega, Madison, WI, USA) at 37˚C for 1 h followed by 85˚C for 10 min. PCR was performed in 20 μl reaction mixture [1X AmpliTaq buffer, 100 ng template cDNA, 200 μM of each dNTPs, 0.5 μM of each primers and 2 U AmpliTaq (Roche)] as follows: 95˚C for 5 min followed by 24 cycles of 95˚C for 1 min, 56˚C for 1 min, 72˚C for 1 min, and the final step of extension was for 10 min at 72˚C. Sequences of the PCR primers for Aurora-A are as follows: upper primer: 5'-GCCTCCTGTGAAGACACCAT-3'; lower primer: 5'-ACTT TGTAACAGAGGGAGCC-3' with an expected product of 471 bp. ß-actin was used as internal control (upper: 5'-GGCG GCACCACCATGTACCCT-3' and downstream: 5'-AGGGG CCGGACTCGTCATACT-3') at 202 bp. Negative control was the amplification omitting the template from the reaction. The reaction products were visualized by electrophoresis of 5 μl reaction mixture at 70 V for 40 min in 2% agarose gel containing 0.5 μg/ml ethidium bromide, and quantitated by densitometry using Gel-Pro Analyzer version 3.1 (Media Cybernetics, Silver Spring, MD, USA).
Real-time polymerase chain reaction. To detect the amplification in cancer samples, real-time PCR was performed in the Rotor-Gene RG-3000 Real-Time Thermal Cycler (Corbett Research, Sydney, Australia), which detects the signal from the fluorogenic probe during PCR. As both the precise amount of genomic DNA and its quality are difficult to assess, we also quantified a control gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH). All data were normalized to GAPDH.
The ratio defining the level of amplification is termed 'Am', and is determined as follows:
T the ratio of gene copy number of Aurora-
N the ratio of gene copy number of Aurora-A to GAPDH (T, tumor tissues; N, corresponding normal tissues).
The kinetic method requires a standard curve which was constructed with serial 10-fold dilutions of specific PCR products. And in this study, we constructed two standard curves with two different pairs of primers used later for real-time quantitative PCR to quantify Aurora-A and GAPDH gene copy number separately.
PCR amplifications were done with SYBR Premix Ex Taq (Perfect Real-Time) Kit (Takara Biotechnology, Dalian, P.R. China) according to the manufacturer's protocol. The amplification mixes (25 μl) contains SYBR Premix Ex Taq 12.5 μl, ROX Reference Dye 0.5 μl, each primer 0.5 μl (200 nM) and template 2 μl (around 20 ng). The fragment of Aurora-A was amplified with the primers 5'-CCTTCGAATGTTGGCAGG AT-3' and 5'-TCCAACACTAACAGACCGCA-3'. Internal control GAPDH used the primers 5'-TGAAGGTCGGAGTC AACGGA-3' and 5'-CATGTGGGCCATGAGGTCCA-3'. PCR was performed as follows: 94˚C for 10 sec followed with 40 cycles of 94˚C for 5 sec and 60˚C for 30 sec. The software Rotor-Gene 5.0 calculated the parameter C t (threshold cycle) and determined the starting copy number in the samples.
We investigated 29 cancer samples and their corresponding normal tissues. The ratio of Aurora-A copy number to the copy number of GAPDH indicated the gene copy number level of Aurora-A.
Western blot analyses. In order to determine the expression levels of Aurora-A in esophageal cancer cell lines and cancer samples, the frozen tissues after trituration and culture cells were lysed in RIPA lysis buffer containing 1X PBS (137 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 , pH 7.4), 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM PMSF, 1 μg/ml aprotinin and 5 μg/ml leupeptin. Lysates were centrifuged at 12,000 g for 15 min at 4˚C. The protein concentration was determined using BCA Protein Assay Kit (Pierce, Rockford, IL, USA). Equal amounts of total proteins were then separated on 12% acrylamide gels using standard sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) techniques. After transfer to nitrocellulose membranes (Optitran, Schleicher&Schuell, Keene N.H., USA), the proteins were detected with anti-Aurora-A antibody (N20; 1:1000; Santa Cruz, CA, USA), followed by anti-goat IgG-horseradish peroxide-conjugated secondary antibody (Zhongshan Co., Beijing, P.R. China) and chemiluminescence luminol detection kit (Santa Cruz). The same membrane was reprobed with anti-ß-actin (AC-15; 1:5000; Sigma, St Louis, MO, USA) as a control for equivalent protein loading.
Results
Amplification of Aurora-A in esophageal cancer cell lines.
Using an Aurora-A gene specific probe and centromere probe for chromosome 20, we detected the Aurora-A gene copy increments in esophageal cancer cell lines by FISH (Fig. 1) . Each numbering included 100-200 metaphase cells, and total amplification rate in each cell type was calculated. Then the cells were assorted into amplification and high amplification of Aurora-A based on the ratio of 20q13.2 to 20q signals. Six out of seven esophageal cancer cell lines have amplified Aurora-A, three of which showed high amplification of Aurora-A (Table I) .
We also found many isochromosomes of 20q13.2, which is a common feature of aneuploidy and gene amplification in cancer.
Amplification of Aurora-A in esophageal cancers. Quantitative real-time PCR was done to detect the amplification of Aurora-A in esophageal cancer tissues. Twenty-nine paired cancer samples and distant normal esophageal epithelium were investigated to evaluate the gene copy level of Aurora-A by using GAPDH as internal control.
GAPDH standard curve was constructed (Fig. 2) and then quantitative real-time PCR was done to detect the GAPDH gene copy number (Fig. 3) . The same experiment was done to detect the Aurora-A gene copy number. The starting copy numbers were determined by the software Rotor-Gene 5.0, Table I . Amplification of Aurora-A in esophageal cancer cell lines.
-----------------------------------------------------------------------------------------------------Ratio a Esophageal cancer Numbered cell ----------------Amplification rate
High amplification cell lines 1-1.5 ≥1. 
(%) (%) -----------------------------------------------------------------------------------------------------
.64 -----------------------------------------------------------------------------------------------------
a Ratio between 20q13.2 and 20q centromere signal number in each cell line. For each cell type, 100-200 cells were counted.
-----------------------------------------------------------------------------------------------------
and all the data were normalized to GAPDH. As showed in Table II , 27 of 29 (93.1%) cancer samples possessed higher Aurora-A gene copy level than their corresponding normal tissues. Therefore Aurora-A is amplified in ESCC.
Overexpression of Aurora-A in esophageal cancers and cancer cell lines. We tested the expression level of Aurora-A gene in 7 esophageal cancer cell lines by semi-quantitative reverse transcription PCR analysis and Western blot assay. We used HLF cell (human lung fibroblast cell) as a normal control. All esophageal cancer cell lines showed overexpression of Aurora-A compared with HLF cells at mRNA level, KYSE70, 410 and ESCC9706 also have higher expression of Aurora-A from protein level detection (Fig. 4) . We also detected mRNA expression level of Aurora-A in esophageal cancer samples (Fig. 5) . Comparison of band densitometry between Aurora-A and ß-actin by software showed 71.1% (27/38) esophageal cancer samples had more than 1.5-fold increase of Aurora-A mRNA level in contrast to paired normal adjacent tissues (Table III) .
In addition to RT-PCR analysis, ten cancer specimens were collected and assayed for Aurora-A expression by Western immunoblot analysis. Six Cancer samples showed increased Figure 2 . GAPDH standard curve by real-time PCR. Four real-time polymerase chain reactions were done with serial 10-fold dilutions of specific PCR products of GAPDH as template (A). The parameter C t (threshold cycle) was determined by software Rotor-Gene 5.0, and the standard curve was constructed based on the C t and the template concentration of the four samples (B). Figure 3 . GAPDH gene copy number was detected by quantitative real-time PCR. Real-time PCR was performed to evaluate the GAPDH gene levels in esophageal cancers, the different color curves represent different samples. Table II . Amplification of Aurora-A in esophageal cancers.
of patients 2 (6.9) 27 (93.1) ------------------------------------------------ protein level of Aurora-A in human esophageal squamous cell carcinoma (Fig. 6 ).
Discussion
Esophageal cancer is the seventh leading cause of cancer death worldwide. In China, more than 90% of esophageal cancer is the squamous cell carcinoma type, and the area of the high incidence of ESCC is in the north. According to epidemiological studies, there are multiple etiological factors, such as nutritional deficiency, toxic stimuli, hot food ingestion and genetic background, contributing to the development of esophageal cancer. Because esophageal cancer usually is not diagnosed until the late stage and the disease has spread, prognosis of esophageal cancer is very poor. Fewer than 20% of people survive more than 5 years (22) , therefore novel approaches to the early diagnosis and treatment of this malignant tumor are urgently needed, and understanding the molecular mechanism of human esophageal squamous cell carcinoma is the key to any such approach.
In our present study, we demonstrated amplification and overexpression of Aurora-A/STK15 in esophageal cancer cell lines and esophageal cancer tissues.
Previous comparative genomic hybridization studies in esophageal cancer cell lines and tissues revealed that 20q amplification is common in esophageal cancers, but the genes involved in 20q gain are poorly identified. Given that the frequent 20q amplification in breast cancer and bladder cancer is often accompanied by the overexpression of Aurora-A (23, 24) , a mitosis regulating gene located on 20q13.2, we proposed Aurora-A as the possible target gene on amplified 20q in the esophageal cancer. In our present study, we identified frequent amplification of Aurora-A locus at 20q13.2 in seven esophageal cancer cell lines by dual-color FISH assay and in cancer samples by real-time PCR assay. Semi-quantitative RT-PCR was used to detect the expression of Aurora-A in esophageal cancer tissues. We found 27/38 (71.1%) esophageal cancers with elevated expression of Aurora-A when compared with corresponding normal tissues, which is consistent with other recent reports that Aurora-A is overexpressed in human ESCC (12, 21) . In addition, there are recent reports showing that the Aurora-A polymorphism is associated with ESCC risk (25, 26) . Although the relationship between the overexpression and polymorphism of Aurora-A needs to be further revealed, the polymorphism in Aurora-A gene was demonstrated to be associated with an increased risk in ESCC, as well as in breast cancer (25) (26) (27) . Therefore, the studies, including ours, strongly suggested Aurora-A involvement in the Chinese esophageal cancer development and progression.
Aurora-A/BTAK/STK15 gene, located in 20q13, frequently amplified chromosome region in many tumors including ESCC shown in our present study, belongs to a serine/threonine kinase family (Aurora kinase family) implicated in equal segregation of chromosomes between daughter cells. Aurora-A is important to centrosome duplication, maturation and accurate separation as well as to bipolar spindle assembly and stability. Its crucial role in the normal cell division suggested that change of Aurora-A expression might contribute to the aberrant cell growth in cancer. In fact, ectopic overexpression of Aurora-A in mammalian cells has been demonstrated to cause centrosome amplification, leading to aneuploidy. More importantly, overexpression of Aurora-A can lead to genetic instability and cause mammary tumor development in transgene mouse, which indicated that overexpressed Aurora-A could function as a potential oncogene causing carcinogenesis in many solid tumors.
Taken together, our present studies on the overexpression and amplification of Aurora-A in ESCC have provided indicative clues to revealing the mechanism of esophageal carcinogenesis and to find regimens to improve survival of esophageal cancer patients. Although the cause which triggers Aurora-A amplification and the mechanism involved during carcinogenesis in human solid tumors still need to be deeply investigated, the efficient therapy targeting Aurora-A in other malignant tumors (28) (29) (30) (31) could also bring hope to esophageal cancer patients if the vital role that Aurora-A plays in esophageal cancer could be addressed further. Table III . Overexpression of Aurora-A in esophageal cancers. ------------------------------------------------- a The samples had >1.5-fold increase of Aurora-A mRNA level compared to that of the normal control.
-------------------------------------------------
- ------------------------------------------------Figure 6 . Aurora-A was overexpressed at the protein level in esophageal cancers. Analysis of Aurora-A protein expression in human ESCC tissues by Western blot assay. Cell lysates were prepared from clinical esophageal cancers and normal adjacent tissues (T, tumor; N, corresponding normal tissues). The same membrane was reprobed with anti-ß-actin as a loading control.
